Company Description (as filed with the SEC)
The principal focus of our strategy is to identify, develop and commercialize treatments for angioedemas that are identified as plasma kallikrein-mediated, which we refer to as PKM angioedemas, including hereditary angioedema (HAE) and idiopathic angioedema. We discovered and developed KALBITOR (ecallantide) using our phage display technology, and since February 2010, we have been selling it in the United States for the treatment of acute attacks of HAE. Outside of the United States, we have established partnerships to obtain regulatory approval for and to commercialize KALBITOR in certain markets and we are evaluating opportunities in others. We are expanding our franchise for the treatment of PKM angioedemas in the following ways: ? Development of diagnostic strategies to assist in the differentiation between histamine-mediated and PKM angioedema. ... More ...